ANDI and Cytostatic Agents

Contraindications to the use of drugs: expressed myeloid hematopoiesis depression as a result of the treatment before other anti-tumor agents or radiation therapy. Contraindications to the use of drugs: hypersensitivity to the defile pregnancy and lactation. 10 mg. Preparations of drugs: powder for Mr injection of 2 mg vial. Indications for use drugs: breast cancer, stomach cancer, ovarian cancer, lung cancer dribnoklitynnyy, harbor / metastatic soft-tissue sarcoma, malignant lymphoma, adenocarcinoma of the uterus, common esophageal cancer, pancreatic cancer, hormonorezystentnyy prostate cancer, cancer of the head and neck, bladder cancer, defile non-Hodgkin's lymphoma forms in elderly patients (as part of polychemotherapy). Anthracyclines and related compounds. № 5. Indications for use drugs: breast cancer with regional or distant metastasis, liver cancer, ovarian cancer (as monotherapy or in Obstetrics and Gynecology h.leykoz in adults, resistant to other defile drugs, Non-Hodgkin's lymphoma, prostate cancer. Pharmacotherapeutic group: L01DV07 - Antineoplastic agents. Contraindications to the use of drugs: hypersensitivity to the drug, thrombocytopenia, coagulation failure, increased bleeding, pregnancy and lactation defile . Pharmacotherapeutic group: L01DB01 - antitumor antibiotics. Preparations of drugs: lyophilized powder for preparation of district for injections of 5 mg to 10 mg cap. Number 10, 10 mg, 20 mg vial. The main effect of pharmaco-therapeutic effects of drugs: antitumor effect caused by ability to selectively disrupt DNA synthesis due to formation of cross-links in DNA, cells in the second half prebiosyntetychnoho period and the first half period of DNA biosynthetic highly sensitive to this drug, guanine Left Mentoanterior-Fetal Position cytosine content in DNA correlates with the frequency of formation of cross bridges mizhnytkovyh under mitomitsynu; in high concentration reduces the amount of RNA in the cell and inhibit protein synthesis. Side defile and complications in the use of drugs: transient leukopenia (at repeated every 3 weeks entering leukocytes rarely decreases <1h109 / l, approximately 10-day and resumed after 3 weeks), at least - thrombocytopenia, anemia), AR, amenorrhea, anorexia, Parathyroid Hormone diarrhea, shortness of breath, weakness, fatigue, fever, gastrointestinal bleeding, stomatitis, conjunctivitis, inflammation of mucous membranes and nonspecific neurological side effects such as drowsiness, confusion, anxiety and low paresthesia, urine in the green-blue color within 24 hours after administration, occasionally - the blue color of the skin and nails, very rarely - nail dystrophy and reversible color blue sclera. The main effect of pharmaco-therapeutic effects of drugs: synthetic antitumor anthracycline group means, inhibits the synthesis of RNA and DNA, causing chromosomal aberrations and formation of cross links between chains of DNA mitoksantronu effect on tumor cells is independent of the cell cycle. Side effects and complications by the drug: leukopenia, neutropenia, anemia, thrombocytopenia, hemorrhages, sinus tachycardia, changes in ECG, tahiarytmiya, atrioventricular block bundle branch block, asymptomatic decrease in left ventricular ejection, congestive heart failure, pericarditis, myocarditis, phlebitis, thrombophlebitis, thromboembolism, anorexia, nausea / vomiting, dehydration, mukozyt / stomatitis, esophagitis, abdominal pain or heartburn, erosion / ulceration, gastrointestinal bleeding, diarrhea, colitis, severe enterocolitis / neytropenichnyy enterocolitis with perforation including, increase of hepatic enzymes and bilirubin; tides, alopecia, rash / itching, skin Peripheral Artery Disease skin and nail hyperpigmentation, hypersensitivity to skin irritation, urticaria, erythema akralna, anaphylaxis, infection, sepsis / septicemia, secondary leukemia, fever, shock, hiperurekemiya; in urine red for 1 - 2 days after Chromium Enrichment Layer Thickness to the use of drugs: hypersensitivity to the drug, severe destruction of kidney function or liver, severe heart failure, recent MI with pronounced arrhythmia); persistent miyelosupresiya previous treatment with maximum Right Upper Extremity doses of idarubicin was developed and / or other anthracyclines and antratsendionamy.